In this online CME self-learning activity:
ADHD is a common neuropsychiatric disorder, estimated to affect 7.2% of school age children worldwide and 11% in the US. The presence of the disorder is often not detectable until school workload increases, and it has a significant impact on child and adolescent development, health, education, and family situations. There is evidence of a wide variability in clinicians’ ability to diagnose ADHD, suggesting opportunities for improvement and a gap in care that might be remedied by CME.
Although ADHD may be linked to a variety of social and environmental factors, including maternal smoking, fetal alcohol syndrome, lead poisoning, and meningitis, genetics also play a large role, with heritability studies showing the likelihood of passing the condition on between 40% and 90%. The exact pathophysiology is unclear, but there is some evidence of decreased brain volume, which may affect executive functioning needed for prioritizing, decision making, motor control, and awareness of space and time. Alterations in dopaminergic, cholinergic, and serontonergic functions have been documented in ADHD, which may impair the ability to delay gratification, resist distractions, regulate arousal, and focus on uninteresting tasks.
The stimulant drug class presently represents first-line pharmacotherapy. There had previously been concern about the health risks of pharmacotherapy. However, time has brought additional experience with the medication, as ADHD medication use has risen by over 35% overall. Another concern in recent years that may have been addressed is prescription drug abuse in children and young adults; research is now finding a significant gap between perceptions of abuse of ADHD stimulant medications and actual rates of misuse and abuse. This activity is intended to be a one-hour learning activity focused on ADHD and its complications, designed to bring healthcare providers up to date in their practice and give them a sense of coming changes to practice and the literature.
The following healthcare professionals: psychiatrists, primary care physicians, pediatricians; physician assistants, nurse practitioners, nurses, and pharmacists who practice in psychiatry; and any other healthcare professionals with an interest in or who clinically encounter pediatric patients with ADHD.
Commercial Support Disclosure: This activity is supported by an educational grant from Shire Pharmaceuticals.
Learners may participate in this activity free of charge.
Release Date: October 06, 2019 -- Expiration Date: October 06, 2021
Faculty: Michael Enenbach, MD
- Faculty member introduction, disclosures, overview of pediatric ADHD
- Major findings from APA 2019, including clinical trial data relevant to both community and health-system practice and recognized barriers to implementing those findings in practice (specific content contingent upon conference content)
- Predicted of applicability to clinical practice and patient cases, where relevant
- Concluding remarks
By the end of the session the participant will be able to:
ACCME Activity #201349349ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.
As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.
Faculty Disclosure: Michael Enenbach, MD , Associate Clinical Professor, UCLA, has no relevant financial disclosures.
Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP, President of ScientiaCME, has no relevant financial disclosures.
*Required to view Printable PDF Version
Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.
Updates in the management of insomnia: Therapeutic updates and optimizing treatment
Bipolar and mood disorder: Therapeutic updates and best practices
Attention Deficit Hyperactivity Disorder (ADHD) in Adults: Updates from APA 2019
Opioid dependence and opioid use disorder: Best practices, barriers in care, and the role of long-acting injectable medication